CrossBridge Bio Secures Significant Financing for Cancer Therapies
CrossBridge Bio, a pioneering biotechnology company specializing in dual-payload antibody-drug conjugates (ADCs), has successfully closed a funding round totaling $10 million. This funding is spearheaded by reputable investors, including TMC Venture Fund and CE-Ventures. With participation from significant entities like Portal Innovations, Alexandria Venture Investments, and Linden Lake Labs, this financing round marks a critical step in the advancement of innovative cancer therapies.
Innovative Approach to Cancer Treatment
The foundation of CrossBridge Bio's technology stems from groundbreaking research conducted by distinguished scientists, Dr. Kyoji Tsuchikama and Dr. Zhiqiang An, affiliated with UTHealth Houston. Their research has paved the way for a unique dual-payload ADC platform that effectively combines established and novel antibodies. This approach incorporates diverse mechanisms of action, making it possible to create an extensive array of ADC programs. These programs promise to deliver specific molecular characteristics, distinct pharmacological actions, and favorable safety profiles across various cancer types.
Focus on CBB-120 Development
With the newly acquired seed capital, CrossBridge Bio aims to expedite the development of its lead candidate, CBB-120. This prospective best-in-class TROP-2 dual-payload ADC targets solid tumors, thereby significantly contributing to the existing ADC therapies. Furthermore, the funds will support the enhancement of the company's proprietary linker technology, which is essential for dual-payload applications. This technology optimization aims to boost the safety and efficacy of both current and future drug candidates in the pipeline.
Leadership and Strategic Growth
The financing round also leads to notable changes within the leadership structure. William McKeon, the President and CEO of the Texas Medical Center (TMC), along with Damir Illich, Ph.D., the Manager of Life Sciences at CE-Ventures, will join CrossBridge Bio’s board of directors. Their expertise in healthcare and life sciences will be invaluable in fostering the company's strategic growth and navigating challenges in the biotechnology landscape.
Positive Impact on Patients
Michael Torres, Ph.D., CEO of CrossBridge Bio, expressed the company’s optimism regarding the support from experienced investors. He emphasized the goal of utilizing the dual-payload ADC technology to produce synergistic therapeutic effects while maintaining a high level of stability. This ensures that the therapeutic agent is released specifically within targeted cancer cells, maximizing treatment efficacy and minimizing side effects commonly associated with existing therapies.
McKeon highlighted the potential global impact of CrossBridge Bio's innovations, stating that the advancements in dual-payload ADCs could significantly change the lives of cancer patients worldwide. Illich echoed this sentiment, expressing excitement over the prospects that lie ahead for CBB-120 and the company’s broader pipeline of therapies.
A Bright Future for CrossBridge Bio
CrossBridge Bio stands at the forefront of a transformative era in cancer treatment. The focus on stable, dual-payload ADC therapeutics offers new hope for tackling various solid tumor types. CBB-120 is poised to make a meaningful impact in the therapeutic landscape, addressing critical challenges such as tumor heterogeneity and resistance commonly faced in cancer therapies today.
About CrossBridge Bio
CrossBridge Bio is redefining the approach to antibody-drug conjugate (ADC) therapeutics. The company is harnessing cutting-edge technology from the labs of Dr. Kyoji Tsuchikama and Dr. Zhiqiang An, focusing on innovative linker technology that enables enhanced stability and payload versatility. This strategic focus aims to expand their portfolio of dual-payload ADC programs targeting solid tumors, particularly through the promising candidate CBB-120. Established during the TMC Innovation’s Accelerator for Cancer Therapeutics program, CrossBridge Bio is headquartered in Houston, TX, and is at the leading edge of next-generation cancer therapies.
Frequently Asked Questions
What is CrossBridge Bio known for?
CrossBridge Bio is known for developing dual-payload antibody-drug conjugates (ADCs) for targeted cancer therapies.
How much funding did CrossBridge Bio secure?
The company secured $10 million in seed financing to support its research and development efforts.
What is the purpose of the new funding?
The funding will accelerate the development of CBB-120 and enhance the company's ADC platform technologies.
Who are the new board members at CrossBridge Bio?
William McKeon and Damir Illich, Ph.D., are joining the board, bringing their expertise in healthcare and life sciences.
What is CBB-120?
CBB-120 is a lead candidate ADC developed by CrossBridge Bio targeting solid tumors, aiming to improve cancer treatment outcomes.